Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication ...

CHICAGO, April 29, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication ...

The xF+ assay integrates with the Tempus multimodal database, supporting therapeutic recommendations and clinical research. Originally introduced in 2022, the xF+ panel covers 523 genes spanning ...

Tempus AI continued to see dramatic revenue and gross profit growth in the first quarter, with year-over-year revenue up 75.4 ...

Adjusted EBITDA improved significantly to $-16.2 million compared to $-43.9 million in Q1 2024, representing a $27.8 million ...

Tempus AI Inc. TEM during the first quarter secured a multi-million dollar deal to build “the world’s largest foundation model for oncology.” “And this is big for a few reasons,” said ...

We recently published a list of 10 Firms Crushing the Market. In this article, we are going to take a look at where Tempus AI Inc. (NASDAQ:TEM) stands against other firms that are crushing the market.

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ultimately be used to develop new cancer drugs. Tempus will use its “vast ...